SAN DIEGO, Sept. 28, 2022 (GLOBE NEWSWIRE) — Shareholder Rights Law Firm Johnson Fistula, LLP announces that a class action lawsuit has been filed on behalf of investors Ampio Pharmaceuticals, Inc. (“Ampio”) AMPE. The class action is on behalf of shareholders who purchased or otherwise acquired the shares between December 29, 2020 and August 3, 2022. Investors are hereby notified that they have until October 17, 2022 to petition the court to appear as lead plaintiff in this lawsuit.

What actions can I take at this time? If you have suffered a loss and would like to learn more about whether you are a Lead Plaintiff, please contact Jim Baker ([email protected]) via email or phone at 619-814-4471. When emailing, please include your phone number.

To participate in this promotion you can click on the following link or copy and paste it into a browser:

There are no costs or obligations for you.

The lawsuit stems from the Company’s misrepresentations regarding the ability of Ampion, its lead product, to treat individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (“OAC”). From 2010 to around March 2022, Ampio conducted numerous clinical studies and analyzes to determine the effectiveness of Ampion. Although confidentially advertised on numerous occasions that Ampion demonstrated a statistically significant reduction in pain associated with symptomatic moderately severe OAC, the company failed to bring Ampion to market. On May 16, 2022, the Company announced that it had formed a special committee to conduct an internal investigation focused on the statistical analysis of Ampio’s AP-013 clinical study and the unauthorized provision of Ampion, which has not yet been approved by the US -US Food and Drug Administration approved. Then, on August 3, 2022, Ampio announced that “at the time of the March 2020 interim per-protocol analysis, senior staff were aware that the AP-103 study did not demonstrate efficacy for Ampion…

Read full story here